Brendan Teehan - Feb 1, 2025 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role
Chief Commercial Officer
Signature
/s/ Kristen Williams, Attorney-in-Fact
Stock symbol
PCRX
Transactions as of
Feb 1, 2025
Transactions value $
$2,645,705
Form type
4
Date filed
2/4/2025, 06:25 PM
Previous filing
Jan 28, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCRX Common Stock Award $0 +54K $0.00 54K Feb 1, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCRX Stock Option (Right to Buy) Award $2.65M +99.5K $26.59 99.5K Feb 4, 2025 Common Stock 99.5K $26.59 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units that vest in four equal annual installments beginning on February 1, 2026, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F2 The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.